A Stanford Nature study shows gut bacteria drive age-related memory loss through vagus nerve inflammation, while new research in Nature Communications, npj Biofilms and Microbiomes, and Microbiology Spectrum reveals that…
The FDA has cleared the first-ever human trial of epigenetic reprogramming longevity therapy, while an AI model published in Cell identifies new drug candidates at unprecedented speed. Together with a…
🔬 Aging is a coordination failure — The 2026 World Congress on Targeting Longevity is reframing aging as a breakdown between biological systems, shifting strategy from single-target drugs to systems medicine. 🤖 AI drug discovery hits clinical scale — Over 173 AI-discovered drug programs are now in human trials with breakthrough Phase I success rates, and new tools can screen millions of compounds in hours. 🫁 Aging lung cells drive respiratory vulnerability — UCSF researchers pinpointed aging fibroblasts as the trigger for the deadly inflammatory overreaction that makes flu and COVID so dangerous in older adults. 🦠 Gut bacteria directly control immunity — Microbes inject proteins into human cells to manipulate immune responses, a discovery that could lead to an entirely new category of microbiome therapies. 💪 Muscle power predicts survival better than strength — Mayo Clinic Proceedings research shows explosive muscle power has a nearly 7x mortality differential between lowest and highest performers in older women.
A landmark UK Biobank study of 60,977 people found that sleep regularity is a stronger predictor of mortality than sleep duration, reducing all-cause death risk by 30 percent. Combined with…
David Sinclair helped make longevity science impossible to ignore. He also became one of its most contested public figures. Part II examines the criticism, contradictory evidence, and scientific arguments that…
The EVOKE and EVOKE+ trials of oral semaglutide in 3,808 Alzheimer’s patients failed their primary endpoints, but stunning biomarker data, positive liraglutide brain volume results, and consistent real-world evidence from…
David Sinclair helped move aging research from the scientific margins into mainstream conversation. Through his Harvard lab, his work on sirtuins, NAD+ biology, epigenetic reprogramming, and his public role as…
Harvard researcher Marinka Zitnik is building AI systems designed to uncover hidden treatments for rare and neglected diseases. Her TxGNN work points toward a future where drug repurposing becomes more…
Every Cure is a nonprofit using AI and drug repurposing to uncover treatments hidden inside existing medicines. Founded by physician-scientist David Fajgenbaum after a repurposed drug saved his own life,…
🧬 - Epigenetic reprogramming enters human trials for the first time, with Life Biosciences' ER-100 receiving FDA clearance for a phase 1 study in optic nerve degeneration, marking the dawn of cellular rejuvenation medicine. 🫁 - An AI-designed molecule for idiopathic pulmonary fibrosis shows clinical promise in a phase 2a trial, proving that algorithmically discovered drugs can survive contact with human biology. 🦠 - Gut bacteria can inject proteins directly into human cells, a newly described mechanism now linked to Crohn's disease inflammation and poised to reshape microbiome therapeutics. 🧠 - Disrupted circadian rhythms are associated with 2.5 times the risk of dementia, reinforcing that sleep timing and biological clock integrity are modifiable targets for brain aging. 💊 - With more than 173 AI-discovered drug programs now in clinical trials and Eli Lilly committing $2.75 billion to AI drug development, the algorithmic era of medicine is no longer theoretical.
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.